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Abstract: The monoamine hypothesis of depression attributes the symptoms of major depressive
disorders to imbalances of serotonin, noradrenaline, and dopamine in the limbic areas of the brain.
The preferential targeting of serotonin receptor (SERT) by selective serotonin reuptake inhibitors
(SSRIs) has offered an opportunity to reduce the range of these side effects and improve patient
adherence to pharmacotherapy. Clozapine remains an effective drug against treatment-resistant
schizophrenia, defined as failing treatment with at least two different antipsychotic medications.
Patients with schizophrenia who display a constellation of negative symptoms respond poorly to
antipsychotic monotherapy. Negative symptoms include the diminution of motivation, interest,
or expression. Conversely to the depressive symptomology of interest presently, supplementation
of antipsychotics with SSRIs in schizophrenic patients with negative symptoms lead to synergistic
improvements in the function of these patients. Fluvoxamine is one of the most potent inhibitors
of CYP1A2 and can lead to an increase in clozapine levels. Similar increases in serum clozapine
were detected in two patients taking sertraline. However, studies have been contradictory as well,
showing no such increases, which are worrying. Clinicians should be aware that clozapine levels
should be monitored with any coadministration with SSRIs.
Keywords: treatment-resistant schizophrenia; SSRIs; augmentation; clozapine; schizophrenia
1. Introduction
The monoamine neurotransmitters serotonin (5-hydroxytryptamine, 5-HT), dopamine,
and norepinephrine are each generated exclusively by their respective populations of neu-
rons. The homeostasis of the monoamine neurotransmitters is maintained by a family of
ATPase active transporters that symport sodium and chloride ions. The monoamine trans-
porters serotonin transporter (SERT), norepinephrine transporter (NET), and dopamine
transport (DAT) regulate the concentrations of serotonin, norepinephrine, and dopamine,
respectively. NET is located in the plasma membrane of noradrenergic neurons, and its
function is to take up released norepinephrine, which was released from the synapse [1].
DAT is responsible for the clearance of dopamine from the extraneuronal space after it is
released from vesicles [2].
These transporters are frequent targets of psychoactive medications and drugs of
abuse. The relative affinities of these drugs for specific populations of monoamine trans-
porters determine their therapeutic utility, liabilities for off-target effects, and potential for
abuse [3]. Pharmacologic manipulation is usually achieved by competitively or allosteri-
cally inhibiting the conformational changes of the transporter, preventing the intracellular
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uptake of neurotransmitter, and causing it to remain available in the synapse at higher
concentrations.
The monoamine hypothesis of depression attributes the symptoms of major depressive
disorders to imbalances of serotonin, noradrenaline, and dopamine in the limbic areas of the
brain. Tricyclic antidepressants showed efficacy in treating depression through their actions
on SERT, NET, and DAT. However, this broad range of activity at these receptors gave rise
to side effects, including dry mouth, hypotension, and urinary retention. The preferential
targeting of SERT by SSRIs offered an opportunity to reduce the range of these side effects
and improve patient adherence to pharmacotherapy. Side effects of SSRIs may arise either
directly from the inhibition of SERT or from downstream effects of increased synaptic sero-
tonin upon other producers of neurotransmitters. In an example of clinical relevance, it is
hypothesized that increased levels of synaptic serotonin may inhibit dopamine-producing
neurons, thereby leading to the debilitating movement disorders of extrapyramidal symp-
toms. Thus, while SSRIs may target SERT almost exclusively, the effects of inhibition are
complex and may impinge upon distinct systems of neurotransmission [4].
While SSRIs are broadly effective in the treatment of depression, it remains necessary
to augment their effects in patients whose symptoms are significantly resistant to SSRIs
alone. Several such SSRI-augmentation strategies are available to clinicians, such as lithium
and triiodothyronine, both of which show only modest augmentation. When such second-
line augmentations prove ineffective, augmentation with atypical antipsychotics may
be considered. When considering the potentially serious off-target effects of atypical
antipsychotics, such as clozapine, it is important to carefully weigh the risks and benefits
of such therapy, especially when the residual disease process includes a durable propensity
for suicidal attempts as a result of their illness [5].
As a result of the need for treatment options in these patients, the FDA has approved
clozapine for the treatment of schizophrenia that has proven resistant to multiple other
treatments and for the prevention of suicide in patients with psychotic disorders. Despite
some demonstrated efficacy in the treatment of psychotic and bipolar depression, seri-
ous off-target effects, which include leukopenia and granulocytopenia, should be strictly
monitored to prevent progression to granulocytopenia. Substantial risks of developing my-
ocarditis, and other adverse cardiovascular and respiratory events, are serious physiological
considerations to be weighed against treatment. Since many patients with schizophrenia
require more than one medication to control their psychiatric symptoms, it is important to
look at medication interactions. Clozapine and SSRIs can have concerning interactions, so
this manuscript aims to create a summary for the clinician regarding interactions between
these two medications.
2. SSRI History, Uses, and Mechanism of Action
2.1. History
First proposed by Schildkraut in 1965 [6], the catecholamine hypothesis suggested
that behavioral states depended on the amount of catecholamines centrally; depression,
therefore, was associated with a deficit of catecholamines, particularly norepinephrine, at
certain brain receptors. Monoamine oxidase inhibitors like iproniazid prevented degrada-
tion of brain norepinephrine and other amines, including serotonin and dopamine [7,8].
Tricyclic antidepressants (TCAs) such as imipramine inhibited the cellular reuptake of
norepinephrine [9]. Feighner’s review of the literature, however, noted that TCAs interact
with multiple receptor sites and can result in atropine-like side effects, making TCAs less
viable for long-term treatment [10]. MAOIs, too, force patients to adopt a strict diet to
prevent tyramine interactions, as these could lead to severe hypertension [10–12].
SSRIs were introduced as comparable antidepressant drugs to TCAs and MAOIs but
with a more tolerable side effect profile. Brambilla et al. conducted a meta-analysis to
evaluate the side effect profiles of SSRIs, particularly fluoxetine, against those of TCAs and
MAOIs and found that a significantly lower percentage of patients treated with fluoxetine
experienced any side effects when compared to those treated with TCAs [13]. Anderson
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et al. showed that patients treated with SSRIs were less likely to discontinue treatment
than those treated with TCAs [14].
2.2. Uses
SSRIs are chiefly used to treat major depressive disorder (MDD), but other indications
include panic disorder, generalized anxiety disorder (GAD), obsessive-compulsive disor-
der (OCD), post-traumatic stress disorder (PTSD), social anxiety disorder, and bulimia
nervosa [15].
An eight-week open study by Compton et al. concluded that sertraline, a commonly-
prescribed SSRI for the treatment of social anxiety disorder, showed a significant reduction
in subject-reported symptoms of depression and subjective levels of distress over the course
of the trial [16]. Salaminios et al. suggested a randomized, double-blind, placebo-controlled
clinical trial protocol for adults aged 18 to 74 presenting to primary care with depression to
investigate the severity and duration of depressive symptoms associated with a response to
sertraline [17]. The results of this 12-week trial, as reported by Lewis et al. showed a weak
association between reduced depressive symptoms at 12 weeks of sertraline treatment
compared with placebo [18]. Secondary analyses of these data showed a reduction of
generalized anxiety symptoms at 6 and 12 weeks compared with placebo, and self-rated
mental health improvement [18]. SSRIs are often effective for both MDD and GAD, as they
tend to be comorbid with each other [15].
Fluvoxamine is commonly used to treat severe OCD in adults [19] and was the first
to be registered to treat OCD in children [20]. Clomipramine, a tricyclic antidepressant,
received FDA approval for the treatment of OCD [21] but exhibited greater total side effects
than fluvoxamine [22]. The most effective treatment strategy is a combination of an SSRI
with cognitive-behavioral therapy (CBT) [23]; in one study, therapy with paroxetine alone
showed an average relapse time of approximately 63 days [24].
Although patients treated for panic disorder did not show SSRIs to be any more effec-
tive than benzodiazepines in a 10-year longitudinal study [25], SSRIs are still considered
first-line therapy for panic disorder. Citalopram, which received FDA approval in August
1998 [26], was shown to be effective for panic symptoms in an open trial [27]. Similar
efficacy against panic disorder was also shown for the enantiomer escitalopram [28], with
a similar side effect profile [29]. A 2005 Dutch study of the cost-effectiveness of panic
disorder showed that SSRI therapy in combination with CBT is more cost-effective than
either therapy alone [30].
Literature supports the treatment of PTSD with SSRIs. Higher doses of escitalopram
(40 mg/d) were shown to reduce major depressive symptoms in patients who did not
respond to doses up to 20 mg/d in an open-label study [31]. A double-blind, placebo-
controlled trial indicated that fluoxetine is also well-tolerated in treating PTSD, with few
significant side effects [32].
Fluoxetine received FDA approval for the treatment of bulimia [21]. While some
placebo-controlled studies have demonstrated a reduction in behavioral symptoms con-
sistent with bulimia, such as self-induced vomiting and binge-eating [33,34], another
placebo-controlled study was limited by a high patient dropout rate [35]. Other studies
evaluating fluvoxamine and sertraline in treating bulimia have been performed but are
limited by small sample sizes [36,37].
2.3. Mechanism of Action
Although the complete mechanism by which SSRIs function is not fully understood,
the literature generally agrees upon the initial step, suppression of the 5-HT firing neurons
leading to greater availability of synaptic 5-HT within the raphe nuclei [38,39]. Sustained
SSRI treatment eventually desensitizes the 5-HT1A autoreceptors (and 5-HT1B autoreceptors
after two to three weeks of therapy), which results in more 5-HT being released per action
potential [38,39]. Sprouse et al. found that fluoxetine inhibited hippocampal cell firing via
5-HT1A receptor activation, despite a decrease in dorsal raphe cell firing [39].
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2.4. SSRIs Side Effects and Safety Concerns
Selective serotonin reuptake inhibitors were developed by Eli Lilly as a means of
achieving the antidepressant effects of serotonin reuptake inhibition alone, thereby limit-
ing the experience of side effects related to the nonselective inhibition of norepinephrine
and dopamine receptors. The improved selectivity decreased the burdens of dry mouth,
hypotension, and urinary retention and demonstrated improved clinical utility and pa-
tient adherence [4]. Nonetheless, SSRIs themselves retain a range of side effects that
have grown in clinical importance as polypharmacy threatens to increase levels of intrasy-
naptic serotonin above intended limits or to create unintended interactions with other
neurotransmitters.
2.5. Serotonin Syndrome
Serotonin syndrome, which results from toxic levels of synaptic serotonin, is becoming
an increasingly common clinical problem. The current gold standard for the diagnosis of
serotonin syndrome is the Hunter serotonin toxicity criteria to achieve a sensitivity of 84%
and a specificity of 97% [40]. These criteria are, in the presence of a serotonergic agent:
1. Spontaneous clonus
2. Inducible clonus and agitation or diaphoresis
3. Ocular clonus and agitation or diaphoresis
4. Tremor and hyperreflexia
5. Hypertonia
6. Temperature > 38 ◦C and ocular clonus or inducible clonus [41]
The most common cause of serotonin syndrome is the administration of multiple
serotonergic drugs that act to increase serotonin synthesis, serotonin receptor agonists,
and/or serotonin reuptake inhibitors. Because serotonergic drugs are metabolized through
the cytochrome P450 (CYP) enzymes CYP2D6, CYP3A4 [40], and CYP2C19 [42], drugs
that decrease the activity of these enzymes can result in a rise to toxic serotonin levels
over an unpredictable length of time. Similarly, because the monoamine oxidase system
degrades serotonin to 5-hydroxyindoleacetic acid for excretion, ref. [40] Monoamine oxidase
inhibitors are considered particularly likely causes of serotonin syndrome [43].
Examples of drugs commonly used in internal medicine that may contribute to the









Treatment for serotonin syndrome includes discontinuation of all serotonergic drugs,
administration of SERT receptor antagonists, such as cyproheptadine, supportive therapy,
and sedation with benzodiazepines [41].
2.6. Persistent Pulmonary Hypertension in Newborns
Analysis of 143,591 pregnancies from the Quebec statistics database demonstrated a
significant association between maternal use of SSRIs after week 21 of gestation and the
occurrence of persistent pulmonary hypertension in newborns. No association was found
for mothers taking SSRIs before week 21 of gestation [44].
2.7. Prolonged QT Interval
The occurrence of Torsades de Pointes, a form of polymorphic ventricular tachycardia
characterized by a prolonged QT interval, is used as a proxy for the potential of medication
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to cause fatal arrhythmias. Although there is only a modest association between prolonged
QT intervals and the actual occurrence of Torsades de Points, no superior clinical indicator
exists. Complicating matters further, there is currently no consensus on what degree of
QT prolongation should be considered clinically significant. QT interval prolongation is
heterogeneous among SSRIs. The relationship between QT prolongation and SSRIs are as
follows:
- No QT prolongation: fluoxetine and sertraline
- QT prolongation only on coadministration with other QT prolongers: paroxetine
- Potential risk of prolonged QT in monotherapy: citalopram (demonstrated) and
escitalopram (potential)
The effects in citalopram and escitalopram, which are dose-dependent, among other
SSRIs, are notable because they are considered first-line drugs due to their otherwise
favorable side-effect profiles, low degree of drug interaction, and low cost. As a result,
alternative drugs should be considered among patients experiencing acute coronary syn-
dromes. Important considerations also include advanced age, which increases the risk for
prolonged QT interval, and poor CYP2C19 metabolism, which may cause supratherapeutic
exposures at therapeutic doses [45].
2.8. Sexual Side Effects
Studies have demonstrated that 90% of men and 96% of women report the experience
of side effects in at least one area of sexual functioning, and 20%–50% experience sexual
side effects sufficiently significant to seek clinical assistance [46]. Serotonin is a known
inhibitor of sexual desire and physical arousal, and orgasm [47]. These effects are thought
to be related to off-target activity at 5HT2 receptors in the brain, affecting psychological,
sexual function, and in the spinal cord, affecting physical aspects of arousal [42]. Although
experimental therapies have attempted to counteract these side effects, the complex inter-
actions that occur during the sexual response cycle may result in successfully addressing a
single facet of sexual dysfunction while failing to address others. In one example, Ahrold
and Meston successfully redressed deficits in women’s genital arousal with the adminis-
tration of ephedrine but did not directly increase mental, sexual arousal. As a result, the
administration of ephedrine did not positively affect the perception of sexual pleasure in
the short term [46].
2.9. Gastrointestinal Side Effects
Off-target stimulation of central and peripheral 5HT3 receptors may result in nausea
with associated vomiting or diarrhea [42].
2.10. Sedation
Paroxetine alone among the SSRIs may cause sedation due to its unique antihistamine
properties [42].
2.11. SSRI Induced Activation
SSRIs have also been implicated in the activation of hypomania in patients who have
an underlying bipolar disorder. In a case report detailing seven patients, they found that
hypomania was uncovered after administration of an SSRI, with paroxetine being one of
the main offenders [48]. Insomnia can also result from SSRI activation [48].
2.12. SSRIs Pharmacokinetics/Pharmacodynamics
SSRIs have good bioavailability in the gastrointestinal tract, with peak serum con-
centrations achieved 5–8 h after oral administration. Bioavailability, which is partially
mediated by the effects of first-pass metabolism, is generally good. For SSRIs with relatively
low bioavailability (e.g., paroxetine ~50%), bioavailability may improve upon achieving
dosages that result in saturation kinetics. High levels of protein-bound transport and large
areas of distribution are observed due to the strong lipophilicity of SSRIs [49].
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SSRIs undergo hepatic metabolism with a half-life of 18–24 h. Fluoxetine is exceptional
in forming a demethylated norfluoxetine metabolite that is active for several days. Most
SSRIs undergo hepatic metabolism by the P450 enzyme CYP2D6. Alternatively, citalopram
and escitalopram are metabolized by CYP2C19, whose levels physiologically decrease with
age, necessitating dosage decreases in the elderly [42]. Importantly, co-administration of
other drugs that reduce the efficiency of these P450 enzymes can produce toxic levels of
synaptic serotonin toxicity in the setting of SSRI therapy. Of note, the catechol intermediate
formed by paroxetine is excreted mainly via a renal route [49].
3. Clozapine
Clozapine was regarded as an atypical when it was first discovered in 1959 because it
was thought that extrapyramidal side effects were a hallmark of antipsychotic efficacy [50],
but its efficacy was not based on the development of these symptoms [51]. However,
development of the drug has been stymied due to reports of patients developing agran-
ulocytosis [52,53]. Careful blood testing at regular intervals and cessation of therapy at
the first sign of possible agranulocytosis are now part of the treatment protocols for cloza-
pine [54,55]. A 2018 study by Munro et al. found Asian populations were as much as
2.4 times more likely to develop agranulocytosis [56]; Moeller et al. found that African-
American patients were twice as likely to have treatment withdrawn because they had a
significantly lower baseline WBC count than non-African American patients [56,57].
Clozapine remains the only effective drug against treatment-resistant schizophrenia,
defined as failing treatment with at least two different antipsychotic medications [58]. In
the clinical trial by Kane et al. patients who failed treatment with haloperidol for six weeks
were then randomly assigned to a 6-week course of either clozapine or chlorpromazine [54].
Mean scores on the brief psychiatric rating scale (BPRS) and the clinical global impressions
(CGI) scale were significantly higher for patients treated with clozapine over those treated
with chlorpromazine, and as many as 30% of patients treated with clozapine showed
a response to the drug [54]. However, its side effect profile (which, in addition to the
aforementioned agranulocytosis, includes sedation, postural hypotension, gastrointestinal
hypomotility, diabetes mellitus, dyslipidemia, and more serious events such as myocarditis
and cardiomyopathy) remains a major cause for concern among clinicians [59].
Clozapine has been demonstrated to lower suicidal behavior amongst inpatients
with schizophrenia. A retrospective study by Modestin et al. showed suicidal behavior
rate to drop from 28% to just 3% while on clozapine, then regression to 18% following
discontinuation of therapy [60]. One of its more unique effects, however, may lie in its
ability to decrease substance abuse. In a randomized trial, clozapine was associated with
decreased cannabis use [61]; a naturalistic study showed a reduction of alcohol use from
54.1 drinking days to 12.5 while on clozapine [62]. A definitive study on clozapine’s ability
to reduce substance use, however, has yet to be performed [63].
Clozapine Mechanism of Action, Pharmacokinetics, and Pharmacodynamics
Clozapine acts at type 2 and type 4 dopamine receptors, type 2 serotonin receptors,
and receptors of norepinephrine, histamine, and acetylcholine [64]. The binding of D2
currently appears to be an obligate property of successful antipsychotic medications.
Clozapine’s ability to bind weakly and transiently differs from strongly binding traditional
antipsychotics like haloperidol. Transient binding of D2 receptors on the striatum confers
antipsychotic properties while minimizing motor side-effects [65]. Whereas D2 receptors
mediate locomotion, attention, sleep, memory, learning, D4 receptors mediate attention,
sleep, memory, learning. Both D2 and D4 receptors act intracellularly by inhibiting adenylyl
cyclase and activating potassium channels. While clozapine binds with greater affinity
to D4 than to D2 receptors, it is notable that D4 is the least abundant class of dopamine
receptors. Both receptors are expressed with greatest density in the striatum and are
important for survival signaling in dopaminergic neurons [66].
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Like other atypical antipsychotics, clozapine acts as a 5HT2A serotonin receptor antag-
onist. 5HT2A receptors are implicated in the pathogenesis of depression, schizophrenia,
and addictive disorders. Additionally, many hallucinogenic drugs of abuse display 5HT2A
agonism [67]. The relatively high affinity of clozapine to 5HT2A receptors is suspected to
be the basis for its superior efficacy in treatment-resistant schizophrenia [68]. Moreover,
while clozapine’s D2 antagonism relieves the positive symptoms of schizophrenia, 5-HT2A
antagonism relieves its negative symptoms [69].
Like SSRIs, clozapine is extensively metabolized by the hepatic cytochrome P450 (CYP)
system. Somewhat conversely to SSRIs, the major metabolizing enzymes for clozapine
are CYP3A4 and CYP1A2, with CYP2D6 playing only a minor role in metabolism. The
activation of CYP1A2 by cigarette abuse may lead to lower serum levels of clozapine than
in nonsmokers. A notable inhibitor of CYP1A2 is the SSRI fluvoxamine. Also of note, the
rate of clozapine metabolism is observed to fall with age, necessitating dosing adjustments.
Clozapine has a half-life of 8 h, with elimination via hepatic and renal routes [70].
4. SSRIs and Augmentation
The antidepressant effects of an SSRI alone may prove insufficient to completely
treat major depression in 29–46% of patients, necessitating the use of adjuvant pharma-
ceutical therapies [71]. One advantage of adjuvant pharmacotherapy is the avoidance
of pharmacotherapy lag time that would otherwise be encountered when transitioning
from one SSRI to another. Over time, potentially effective pharmaceutical adjuvants have
included non-SSRI antidepressants, bupropion, lithium, triiodothyronine, and atypical
antipsychotic medications [5]. The need for continuous clinical monitoring of levels of
lithium and triiodothyronine has made them relatively unpopular as treatment choices
for clinicians. Likewise, the narrow therapeutic applications of lithium and the potential
side-effects of triiodothyronine in otherwise euthyroid patients limit the utility of these
drugs as adjuvants to SSRIs [72].
The mechanism by which atypical antipsychotics enhance the action of SSRIs is
unknown, and their addition may cause both increased efficacy or increased off-target
effects [5]. Studies by Danovich et al. directly measured changes in the levels of GABAA
β2/3 receptor protein expression and phosphorylation levels in cultured cortical cells
derived from rats, upon administration of either haloperidol plus fluvoxamine or cloza-
pine alone. In experiments testing the combination of haloperidol and fluvoxamine, the
administration of both drugs together showed the inducement of GAD67 and PKCβ2
genes associated with GABAergic transmission that were not activated by either of these
drugs alone. Thus, in the case of haloperidol and fluvoxamine, augmentation therapy has
shown the capacity to not only amplify the efficacy of pharmacotherapy but to exhibit
novel therapeutic properties. These investigators noted that some changes affected by
the combination of the haloperidol and fluvoxamine were similar to the cellular effects
observed with the addition of clozapine alone [73]. Despite acknowledged limitations, this
study is important because it elucidates at least one potential mechanism for the synergy
between SSRIs and antipsychotic medications, which are largely unknown otherwise.
Separately, the failure of some instances of SSRI monotherapy for major depression
has been attributed to the SSRI’s moderate off-target suppression of norepinephrine levels,
which are experimentally demonstrable. The demonstrated ability of aripiprazole to
attenuate these off-target effects on norepinephrine is another putative mechanism for the
effectiveness of SSRI augmentation [74,75].
While quetiapine and aripiprazole have shown the most efficacy for SSRI augmenta-
tion in treatment-resistant depression [72], olanzapine has demonstrated superior efficacy
as an SSRI augmenter in treatment-resistant panic disorder [76].
Patients with schizophrenia who display a constellation of negative symptoms re-
spond poorly to antipsychotic monotherapy. Negative symptoms include the diminution
of motivation, interest, or expression. These symptoms are often responsible for a high pro-
portion of morbidity in schizophrenia [77]. Conversely to the depressive symptomology of
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interest presently, supplementation of antipsychotics with SSRIs in schizophrenic patients
with negative symptoms lead to synergistic improvements in the function of these patients.
Second-generation antipsychotics (SGAs) are also associated with the development of
hyponatremia. Clozapine is one of the most common SGAs associated with the develop-
ment of hyponatremia [78]. The average drop in sodium levels was around 112 mmol/L
and returned to normal levels once the SGA was stopped [78]. This is important to note this
common association as hyponatremia is also a side effect of SSRI use [79]. Using both of
these together could lead to severe hyponatremia, which should be monitored to prevent.
In summary, although the augmenting capabilities of atypical antipsychotics are
clinically appreciated for the augmentation of SSRI therapies, our understanding of the
exact mechanisms of augmentation remain in their infancy. However, where mechanisms
have been partially elucidated, it appears that mechanism of actions for combination
therapy are distinct from either drug in monotherapy.
5. Drug Interactions with Clozapine Levels/Drug Interactions
The cytochrome P450 system plays a significant role in the metabolism of clozap-
ine [80] and, thus, drug-drug interactions can result, and drug interactions can also affect
clozapine levels in the body. CYP1A2 is the primary metabolizer of clozapine, which it
converts to norclozapine; Bertilsson et al. demonstrated that N1- and N7-demethylation
of caffeine correlated strongly with CYP1A2 activity and clozapine clearance [81]. Flu-
voxamine is one of the most potent inhibitors of CYP1A2; a case report of a 44-year-old
male patient showed that he exhibited up to 4160 mcg/L of plasma clozapine (normal
range 200–600 mcg/L) after the addition of fluvoxamine [82]. Similar increases in serum
clozapine were detected in two patients taking sertraline [83]. Smoking can also induce
CYP1A2 and reduce serum clozapine levels [84]. Haring et al. described a 20% lower
plasma concentration of clozapine in smokers when compared with non-smokers [85]; Wet-
zel et al. describes a similar decrease in smokers [86]. Subsequent studies observed a com-
parable decrease in plasma clozapine concentration in smokers to an increase in CYP1A2
activity measured by caffeine clearance [87,88]. The proton pump inhibitor omeprazole
also induces CYP1A2 and reduced plasma levels of clozapine in two patients [89].
Clozapine can also be metabolized by CYP3A4 to clozapine-N-oxide, but this is
thought to be a minor pathway [90]. Concomitant administration of erythromycin, an
inhibitor of CYP3A4, caused clozapine toxicity and elevated serum levels in a patient [91].
A subsequent 1999 study found no significant differences in clozapine serum concentration
upon erythromycin administration, though Hagg et al. acknowledge that this result may
have been influenced by a short 9-h erythromycin pre-treatment period [92]. A similar lack
of effect on clozapine concentration was also exhibited by itraconazole, another CYP3A4
inhibitor [93]. Nefazodone, another CYP3A4 inhibitor [94], showed only minimal increases
on clozapine and norclozapine levels in a study of six patients [95]. Fluoxetine, a common
SSRI used for depression, has been known to increase clozapine levels. There have been
different studies that have reported differing amounts in the increase, but fluoxetine in
these studies have shown to increase clozapine levels between 40% and 70% [96].
There is a relative lack of data amongst the literature where other CYPs are concerned.
In vitro studies have shown that clozapine can inhibit CYP2C9, CYP2C19, CYP2D6, and
CYP3A [97], with a possible preference for CYP2D6 [98]. Data on the possible interaction
between clozapine and paroxetine, a potent inhibitor of CYP2D6, are somewhat contradic-
tory [99]. Centorrino et al. reported a significant 56.6% serum clozapine level increase with
concomitant paroxetine treatment [100], while Wetzel et al. reported paroxetine did not
cause significant pharmacokinetic interactions at a dose of 20 mg/day [86].
Clozapine levels are also associated with infection-related inflammation, with a me-
dian increase of 48% in inflammation based on a CRP of 5 mg/L or higher [101,102].
One recent case study of a 46-year-old nonsmoker with schizophrenia examined the re-
lationship between clozapine levels and COVID-19 infection; however, measurement of
CRP failed during an episode where the patient’s serum clozapine level tripled in the
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presence of pneumonia and COVID-19 [103]. Another patient who had received the Pfizer-
BioNTech vaccine for SARS-CoV-2 had his clozapine level double after he experienced
adverse effects four days post-vaccination; these were later attributed to similar CYP1A2
inhibition mechanisms [104]. In any case, the literature recommends monitoring the cloza-
pine plasma concentration in the presence of infectious symptoms or reducing the dose
in half; the dosage can be resumed within three days of symptom resolution or CRP
normalization [105].
6. Clinical Studies: Safety and Efficacy
A subset of patients will fail to respond or only partially respond to clozapine, leading
clinicians to seek an additional medication for concomitant use with clozapine to improve
treatment outcomes. Patients suffering from co-existent depression may benefit from
adding an SSRI to their clozapine treatment regimen. Studies have investigated the safety
and efficacy of clozapine combination therapies with various SSRIs, including fluvoxamine,
paroxetine, sertraline, fluoxetine, and citalopram.
Fluvoxamine is an SSRI that has been more extensively studied with clozapine com-
pared to other SSRIs. Fluvoxamine is an inhibitor of cytochrome P450 (CYP450) isoenzymes,
particularly CYP1A2 and, to a lesser degree, CYP2C19 and CYP3A4 [106–109]. CYP1A2 is
the main isoform in clozapine metabolism, and thus concomitant use of clozapine with
fluvoxamine may hinder clozapine metabolism and potentially cause adverse side effects.
Many studies have been carried out to analyze the degree to which fluvoxamine increases
plasma levels of clozapine and its metabolites, N-desmethylclozapine and clozapine N-
oxide [110,111]. All studies investigating the effects of fluvoxamine, as described in Table 1,
observed increased levels of clozapine, N-desmethylclozapine, and clozapine N-oxide
following coadministration of fluvoxamine and clozapine [100,107,112].
Szegedi A et al. conducted a study in 1999 to examine the serum concentrations
for clozapine and its metabolites (N-desmethylclozapine, clozapine N-oxide) before and
after coadministration with fluvoxamine [107]. The study included a total of 16 patients
suffering from schizophrenia with predominant negative symptomology (n = 15) or delu-
sional disorder (n = 1). All patients were treated for a minimum of six weeks. Initial
treatment involved a monotherapy with clozapine (2.5–3.5 mg/kg; 125–250 mg/day),
followed by an add-on therapy of 50 mg of fluvoxamine. Increased serum concentrations
of clozapine and its metabolites were observed following the addition of fluvoxamine
to the treatment regimen (day 7: clozapine serum concentrations increased 2.3-fold, N-
desmethylclozapine increased 2.1-fold; day 14: clozapine serum concentrations increased
2.6-fold, N-desmethylclozapine increased 2.6-fold). However, no significant changes in
the frequency or severity of treatment-related adverse effects were reported despite the
increase in clozapine serum concentrations.
The study went on to conclude that the concomitant use of clozapine and fluvox-
amine does, in fact, cause an increase in circulating concentrations of clozapine and N-
desmethylclozapine and clozapine N-oxide, as predicted [107]. However, coadministration
of the two drugs was well-tolerated by patients, causing no apparent critical side effects
despite the increased clozapine, N-desmethylclozapine, and clozapine N-oxide serum
concentrations. This finding was inconsistent with previous studies that reported more
pronounced changes in laboratory and ECG parameters with increased serum clozapine
levels [107,113,114]. This inconsistency may support a current hypothesis that increasing
clozapine dosage and the addition of fluvoxamine do not have the same effects on the
patient, despite both causing an increase in circulating clozapine concentrations. Psy-
chopathology improvement was observed in clozapine monotherapy and continued after
the addition of fluvoxamine. Overall, findings suggest that a combination treatment of
clozapine with fluvoxamine can be an effective treatment option for patients suffering from
schizophrenia with co-existent depression but should only do so if the patient’s clozapine
serum concentrations are being closely monitored.
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Another study investigating the therapeutic efficacy of clozapine and fluvoxamine
coadministration looked specifically at the effects of fluvoxamine on clozapine-related
weight gain, hyperglycemia, and lipid abnormalities [112]. Treatment-resistant inpatients
with a DSM-IV schizophrenia diagnosis (n = 68) were randomly assigned to 2 treatment
groups for 12 weeks; monotherapy group (n = 34) received clozapine (≤600 mg/day),
coadministration group (n = 34) received fluvoxamine (50 mg/day) plus low-dose clozapine
(≤250 mg/day). The monotherapy group showed a significant increase (p < 0.05) in body
weight, BMI, and serum glucose after treatment compared to baseline. Bodyweight, BMI,
and serum glucose also increased in the coadministration group; however, none were
found to be statistically significant. At week 12, the monotherapy group had significantly
higher glucose (p = 0.035), triglyceride (p = 0.041), and norclozapine (p = 0.009) compared
to the coadministration treatment group. Overall, the results from the study provided
evidence that the concomitant use of clozapine and fluvoxamine can attenuate weight gain
and metabolic disturbances. Additionally, plasma levels of the metabolite norclozapine
were specifically found to be associated with increases in weight, serum glucose, and
triglyceride levels; circulating clozapine levels were not associated with these parameters.
One study investigated the therapeutic efficacy of adding citalopram to a clozapine
treatment regimen in patients with schizophrenia by identifying potential drug interactions
that would hinder the metabolism of clozapine. This was a preliminary study that used
psychiatric unit inpatients receiving clozapine treatment for refractory schizophrenia but
still suffered from co-existent depression that necessitated treatment (n = 5). Participants
received an initial treatment of clozapine monotherapy that was administered at a constant
dose (500–600 mg/day) for two weeks. All baseline clozapine plasma levels were obtained
and recorded. Citalopram (20 mg/day) was then added to the treatment regimen for a
minimum of two weeks. Plasma clozapine levels were obtained on day seven and day 14
of concomitant drug use. Samples were routinely taken 12 h after the night-time dose of
clozapine. Clozapine concentration values were determined via high-performance liquid
chromatography. Data obtained from the coadministration of citalopram with clozapine
were as follows: plasma clozapine levels decreased in three patients (patients 1, 3, 5),
increased in one patient (patient 2), and remained unchanged in one patient (patient
4). The overall trend from these data suggest citalopram generally causes a decrease
in plasma clozapine and norclozapine levels. Citalopram did not appear to affect the
relationship between clozapine and its metabolites as the study found the ratio of clozapine
to norclozapine plasma levels remained much unchanged. This suggests that citalopram
does not appear to have any obvious effects on clozapine metabolism, which is an important
distinction from other SSRIs that do interfere with the metabolism of clozapine. The cause
for fluctuations in clozapine plasma levels was unclear, but the study attributed this to
most likely be due to the variations in absorption, distribution, and metabolism unique
to each participant. Based on the limited evidence obtained from the preliminary study,
citalopram appears to potentially be the SSRI of choice in those taking clozapine. However,
a larger study must be carried out to increase the statistical significance of the results.
Spina E. et al. conducted a study to determine the therapeutic efficacy of two SSRIs,
paroxetine and sertraline, when added to a clozapine treatment regimen in patients with
schizophrenia [115]. The study was designed as an open pharmacokinetic investigation
and observation were limited to the first three weeks of coadministration of clozapine
with paroxetine or sertraline. Seventeen outpatients were selected to participate, 11 males
and six females (n = 17), ranging in age from 29 to 55 years old, and had been previously
given a DSM IV diagnosis of schizophrenia (n = 13) or schizoaffective disorder (n = 4).
All participants suffered from co-existent depression that necessitated treatment with an
SSRI. Patients were initially treated with a constant dose of clozapine for a minimum of
three months; clozapine dose ranged from 200 to 400 mg/day between patients. Following
the establishment of steady-state clozapine levels, one of the two SSRIs was added to the
daily treatment regimen; paroxetine (20–40 mg/day; n = 9) or sertraline (50–100 mg/day;
n = 8). Doses for all medications were kept constant throughout the entire study period.
Neurol. Int. 2021, 13 455
High-performance liquid chromatography (HPLC) was used to determine the steady-state
plasma concentrations of clozapine, norclozapine, and clozapine N-oxide, according to
Avenoso et al. [116].
The results from the study showed the addition of paroxetine at 20 to 40 mg/day to
patients stabilized on clozapine therapy resulted in a significant elevation in the serum con-
centrations of clozapine. Paroxetine also appeared to cause an increase in the concentration
of the clozapine metabolites, norclozapine and clozapine N-oxide. Norclozapine plasma
levels significantly increased (p < 0.05), while clozapine N-oxide levels only showed a slight
increase which was not statistically significant. Paroxetine is known to be a potent inhibitor
of CYP2D6, which plays a key role in clozapine metabolism. Investigators believe the
inhibitory effects of paroxetine seem to be mediated or modulated via pathways other than
N-demethylation and N-oxidation. After three weeks of coadministration with paroxetine,
steady-state plasma levels for clozapine and norclozapine were an average of 31% and
20% higher, respectively, compared to baseline levels. This paroxetine-induced elevation
of circulating clozapine levels was not associated with enhanced efficacy or clinically
linked adverse events. Additionally, despite this increase in plasma levels, paroxetine
did not alter the ratios between clozapine and its metabolites, which remained consistent
throughout the investigation. In contrast, sertraline was not found to significantly modify
mean plasma concentrations of clozapine and its metabolites, causing an 11% increase in
clozapine plasma levels and a 5% increase in norclozapine. This drug combination was
also well-tolerated by participants, demonstrating a rise in clozapine plasma levels was
not correlated to a rise in adverse side effects. In summary, the findings from this study
suggest sertraline may be an acceptable treatment option for patients taking clozapine, but
strongly advise when paroxetine is co-administered with clozapine that clinicians provide
patients with careful clinical observation and monitoring. Caution with concomitant use of
paroxetine is particularly important as the inhibitory effect of paroxetine on CYP enzymes
is concentration-dependent, and this relationship may be amplified at higher doses due to
its non-linear pharmacokinetics [117,118].
Centorrino, F et al. compared the therapeutic efficacy of three different SSRIs, flu-
oxetine, paroxetine, and sertraline, when added to a clozapine treatment regimen for
patients suffering from schizophrenia [100]. The main objective of the study was to identify
any potential drug interactions between the SSRIs and clozapine that would hinder the
metabolism of clozapine. Such interactions are of interest because of the limited tolerability
of high doses and circulating concentrations of clozapine [119]. These interactions with
clozapine likely reflect the antagonistic interactions of SSRIs with the genetically complex
hepatic cytochrome P450 oxidase isozymes that play key roles in metabolizing exogenous
compounds [120–123]. Fluoxetine interacts with CYP2D6, CYP2C19, and CYP3A3-4; ser-
traline also interacts with these same CYP isozymes plus CYP1A2; and paroxetine mainly
interacts with CYP2D6 but may also potentially interact with CYP3A3-4 [120,121,123–125].
This study assessed serum concentrations of clozapine and norclozapine in 80 psychiatric
patients, matching for age and clozapine dose. The patients received either clozapine
alone (mean dose = 279 mg/day) or in combination with one of the three SSRIs: fluoxetine
(mean dose = 39.3 mg/day), paroxetine (mean dose = 31.2 mg/day), or sertraline
(mean dose = 92.5 mg/day). Each patient’s clozapine dose was stable for a minimum of
1 month before serum sampling. The serum concentrations of clozapine and norclozapine
were obtained using liquid chromatography and computerized ultraviolet spectrophotome-
try. In patients taking SSRIs, the sum of clozapine and norclozapine plasma levels averaged
approximately 43% higher than patients taking clozapine alone. Findings also suggest
the risk of clozapine levels higher than 1000 ng/mL was 10-fold greater (25%) in patients
taking any of the 3 SSRIs, with minor differences between the individual SSRIs, indicating
these SSRIs can increase circulating levels of clozapine and norclozapine to potentially
toxic levels. In conclusion, the study recommended patients be monitored closely when
taking clozapine in combination with an SSRI, especially when the daily clozapine dose
exceeds 300 mg or 3/5 mg/kg.
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Spina et al. looked at fluoxetine and its effects on the plasma concentrations of cloza-
pine and its major metabolites. Patients were stabilized on clozapine, 200–450 mg/day,
and then received 20 mg/day of fluoxetine for eight consecutive weeks. The mean plasma
concentrations of clozapine were increased significantly by 58%, norclozapine by 36% and
clozapine N-oxide by 38%. The drug combination was well tolerated. They concluded
that clozapine levels should be monitored if fluoxetine is started [126]. However, a fatal
drug interaction was noted in a case report between clozapine and fluoxetine. The de-
creased in this case report had toxicity levels of both clozapine and fluoxetine in his blood.
The deceased also had pulmonary edema, visceral vascular congestion, paralytic ileus,
gastroenteritis, and eosinophila, which are associated with clozapine toxicity [127]. This
highlights the importance of monitoring of drug levels when using these two medications.
Rahman, MS et al. discussed a case report involving the treatment of clozapine-
induced obsessive-compulsive disorder (OCD) with sertraline, taking advantage of ser-
traline’s lack of liver enzyme competition [128,129]. The patient in the case report was a
39-year-old white male with a 20-year history of paranoid schizophrenia. He had been
previously treated with clozapine, which significantly improved his psychotic symptoms,
but he, unfortunately, developed severe clozapine-induced OCD behaviors two years into
treatment and was forced to discontinue the clozapine therapy. Other treatment options
were not effective for the patient. Due to a lack of additional treatment options, the patient
was restarted on a clozapine treatment regimen, but this time with the addition of an SSRI
to avoid a return of OCD behaviors. The initial SSRI used for the patient’s OCD treatment
was fluvoxamine (50 mg/day). The patient’s OCD behavior did improve with fluvoxamine
(150 mg/day). However, this SSRI caused clozapine plasma levels to rise to potentially
toxic amounts over 700 ng/mL, and the patient responded poorly to medication adjust-
ments to account for this fluvoxamine-induced increase (325 mg/day clozapine, 50 mg/day
fluvoxamine). Fluvoxamine was then replaced with sertraline (100 mg twice daily). Ser-
traline proved to be more effective compared to fluvoxamine. The patient’s psychotic
symptoms and obsessive-compulsive behaviors were well controlled by the combination.
Sertraline also did not affect clozapine plasma levels or its efficacy. In conclusion, this case
report demonstrated that SSRIs can effectively treat clozapine-induced ODC behaviors.
Comparison of the two SSRIs showed fluvoxamine was effective in treating the clozapine-
induced OCD behavior but negatively interfered with clozapine metabolism and, as a
result, significantly increased clozapine plasma levels to potentially toxic levels. Sertraline
was selected as the preferred SSRI of choice for the treatment of clozapine-induced OCD
behavior because it proved to be both effective and did not cause a significant increase in
clozapine plasma levels.
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Table 1. Clinical studies combining clozapine with SSRIs.
Author (Year) Drugs Studied/Objective Groups Studied and Intervention Results and Findings Conclusions
Szegedi A. et al.
(1999)
[107]








The study examined serum
concentrations for clozapine and
coadministration of fluvoxamine. Patients
were treated for 6 weeks or more. Initial
treatment was a monotherapy with
clozapine (2.5–3.5 mg/kg;
125–250 mg/day), followed with an
add-on therapy of 50 mg of fluvoxamine.
Increase in serum concentrations of clozapine and
its metabolites observed following addition of
fluvoxamine to treatment regimen (Day 7:
clozapine serum concentrations increased 2.3-fold,
N-desmethylclozapine increased 2.1-fold; Day 14:
clozapine serum concentrations increased 2.6-fold,
N-desmethylclozapine increased 2.6-fold). No
significant changes in adverse effects were
reported (frequency, severity) despite increased
clozapine serum concentrations with concomitant
drug administration.
Concomitant use of clozapine and
fluvoxamine was well tolerated, critical
side effects absent. Psychopathology
improvement observed in clozapine
monotherapy and continued after
addition of fluvoxamine. Combined
treatment should only be prescribed
under close monitoring of clozapine
serum concentrations.
Mong-Liang L et al.
(2004)
[112]
To demonstrate the effects




Treatment-resistant inpatients with a
DSM-IV schizophrenia diagnosis (n = 68)
randomly assigned to 2 treatment groups
for 12 weeks; monotherapy group (n = 34)
received clozapine (≤600 mg/day),
coadministration group (n = 34) received
fluvoxamine (50 mg/day) plus low-dose
clozapine (≤250 mg/day).
Monotherapy group showed significant increase
(p < 0.5) in body weight, BMI, serum glucose after
treatment than at baseline; increase also seen in
coadministration group but not statistically
significant. At week 12, monotherapy group had
significantly higher glucose (p = 0.035), triglyceride
(p = 0.041), and norclozapine (p = 0.009) compared
to coadministration group.
Results suggest concomitant use of
clozapine and fluvoxamine can attenuate
weight gain and metabolic disturbances.
Plasma levels of norclozapine, but not
clozapine, found to be associated with
increases in weight, serum glucose, and
triglyceride levels.








regimen in patients with
schizophrenia
Initial treatment: monotherapy of
clozapine administered at constant dose
(500–600 mg/day) for 2 weeks; baseline
clozapine plasma levels recorded.
Citalopram (20 mg/day) was then added
to the treatment regimen for a minimum
of 2 weeks. Plasma clozapine levels were
obtained on day 7 and day 14 of
concomitant drug use. Samples drawn
12 h. after night-time dose of clozapine.
Clozapine plasma levels increased in only one
participant (patient 2). Plasma levels remained
unchanged in patient 4 but decreased in the
remaining three patients (patients 1, 3, 5). Overall,
small decreases in plasma clozapine and
norclozapine levels observed; ratio of
clozapine:norclozapine remained much the same.
Citalopram had no clear effect on
clozapine metabolism; important
distinction from other SSRI’s that do
interfere with clozapine metabolism.
Based on limit evidence, study finds
citalopram to be the potential SSRI of
choice in those taking clozapine. Larger
study needed to increase
significance of results.
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Table 1. Cont.
Author (Year) Drugs Studied/Objective Groups Studied and Intervention Results and Findings Conclusions




therapeutic efficacy of 2
SSRIs, paroxetine and
sertraline, when added to a
clozapine treatment
regimen in patients with
schizophrenia, ensuring no
drug interactions exist that
would hinder the
metabolism of clozapine.
17 outpatients selected: 11 males 6 females
(n = 17), ages 29–55 years old, and given DSM
IV diagnosis of schizophrenia (n = 13) or
schizoaffective disorder (n = 4). Patients treated
with constant dose of clozapine for minimum
of 3 months, then either 20–40 mg/day of
paroxetine (n = 9) or 50–100 mg/day of
sertraline (n = 8) was added to daily treatment
regimen. Steady-state plasma concentrations of
clozapine, norclozapine and clozapine N-oxide
assayed by HPLC.
Paroxetine found to cause a significant
increase in clozapine plasma levels
(p < 0.01): baseline = 337 ± 83 ng/mL,
week 3 = 441 ± 141 ng/mL. Paroxetine also
found to significantly increase norclozapine
plasma levels (p < 0.05). Paroxetine did not,
however, alter ratios between clozapine and
its metabolites. On the other hand,
sertraline did not significantly modify
mean plasma concentrations of clozapine
and its metabolites.
Clozapine coadministration with paroxetine or
sertraline was well tolerated.
Findings suggest metabolism of clozapine is
not affected by sertraline, while paroxetine, a
potent inhibitor of CYP2D6, does have an effect
and appears to inhibit metabolism of clozapine.
While sertraline may be safely added to
patients on maintenance treatment with
clozapine, careful clinical observation and
monitoring of a patient is recommended when





therapeutic efficacy of 3
SSRIs, fluvoxamine,
paroxetine, and sertraline,




drug interactions exist that
would hinder the
metabolism of clozapine.
Study assessed serum concentrations of
clozapine and norclozapine in 80 psychiatric
patients, matched for age and clozapine dose,
given clozapine alone
(mean dose = 279 mg/day) or in combination
with one of the three SSRIs: fluoxetine
(mean dose = 39.3 mg/day), paroxetine
(mean dose = 31.2 mg/day), or sertraline
(mean dose = 92.5 mg/day).
In patients taking SSRIs, the sum of
clozapine and norclozapine plasma levels
averaged approximately 43% higher than
patients taking only clozapine. Findings
also suggest the risk of levels higher than
1000 ng/mL was 10-fold greater (25%), in
patients taking any of the 3 SSRIs, with
minor differences between the individual
SSRIs.
SSRIs can increase circulating levels of
clozapine and norclozapine to potentially toxic
levels. Patients should be monitored closely
when taking clozapine in combination with an
SSRI, particularly especially when the daily











Patient was a 39-year-old white male with a
20-year history of paranoid schizophrenia;
previous clozapine treatment regimen
significantly improved psychotic symptoms,
but patient developed severe OCD behavior
2 years into treatment and forced to
discontinue clozapine therapy. Initial treatment
(325 mg/day clozapine, 50 mg/day
fluvoxamine). Fluvoxamine discontinued,
substituted for sertraline (100 mg b.i.d.) and
raised clozapine to 475 mg/day.
The patient’s OCD behavior did improve
with fluvoxamine (150 mg/day), however,
the SSRI caused clozapine plasma levels to
rise over 700 ng/mL. Fluvoxamine was
replaced with sertraline (100 mg b.i.d.).
Sertraline was more effective compared to
fluvoxamine and patient’s psychotic and
obsessive-compulsive symptoms were well
controlled. Sertraline did not affect
clozapine plasma level or efficacy.
SSRIs can effectively treat clozapine-induced
ODC behaviors. Fluvoxamine was effective in
treating OCD but caused significant increases
in clozapine plasma levels. Sertraline was also
found to be effective and did not cause
significant increases in clozapine plasma levels.
Neurol. Int. 2021, 13 459
7. Conclusions
SSRIs have historically improved upon the mechanisms of action and consequent
side effect profiles of tricyclic antidepressants and have become the first-line treatment of
choice for major depression. Nonetheless, SSRI monotherapy fails to resolve depression in
a significant number of patients. Atypical antipsychotics, such as aripiprazole, quetiapine,
ziprasidone, olanzapine, and clozapine, have shown efficacy in improving the effective-
ness of SSRIs in the treatment of major depression, panic disorder, obsessive-compulsive
disorder, and other psychiatric conditions that prove refractory to first-line SSRI therapy.
Although little is known about the mechanisms of action in these augmented therapies,
some studies have shown not only augmentation of first-line mechanisms but also the
activation of novel mechanisms that are not activated by either drug in monotherapy.
Clozapine, although carrying a particularly onerous burden of serious off-target effects,
shows unique efficacy in the treatment of treatment-resistant depression. The substantial
risks of clozapine’s potentially permanent and deleterious off-target effects are balanced
in some patients by the need to control the otherwise unacceptable risk of suicidality in
some patients. Although our understanding of the mechanisms these mechanisms of action
for combinatorial therapy with SSRIs and atypical antipsychotics remains in its infancy,
the potential for the discovery and exploitation of novel therapeutic mechanisms appears
promising and warrants further scrutiny. Initial in vitro studies on the combinatorial
mechanisms of fluvoxamine and haloperidol have demonstrated mechanical similarities to
clozapine. Given clozapine’s extreme off-target effects, one direction for further study may
be in vivo trials of such combinatorial therapies as a superior alternative to clozapine as
mechanism of augmentation, although the risks of adding fluvoxamine to another SSRI
warrant monitoring for the development of serotonin syndrome.
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